ADVB — what changed in the latest 10-K

A section-by-section comparison of ADVB's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.

Comparing 10-K · 2026-10-13 vs the prior 10-K · 2025-10-08

Section	Outcome	Added	Removed	Minor	Unchanged
Business	Text added/removed	+69	−255	~1	8
Risk factors	Text added/removed	+64	−247	~26	80
Legal proceedings	No paragraph-level changes	0	0	0	1
MD&A	Text added/removed	+91	−94	~1	1
Market risk (Item 7A)	No paragraph-level changes	0	0	0	1

Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.

Representative excerpts

Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.

Business

Text added vs the prior filing · source: 10-K · 2026-10-13

We are a holding company incorporated in the State of Nevada. In April 2026, we acquired 100% of equity interests of Acellent Technologies (Hong Kong) Co. Limited (“Acellent”), which develops and operates the FinTruth Financial Verification Agent Platform (“FinTruth”), an enterprise AI financial ver…
Prior to our shift to developing our AI application through FinTruth, we were focused on developing lab devices and chemicals in order to find and study cancer cells in a patient’s blood, with the eventual goal of helping doctors detect and monitor cancer through simple blood tests. Our products inc…
Our shift to becoming an AI financial verification company is driven by what we believe are the following key drivers of demand for AI financial verification: (1) the wide use of large language models and AI agents by financial institutions in credit analysis, investment research, risk assessment an…
The market for AI verification remains at an early stage, and adoption will depend on financial institutions’ technology budgets, regulatory requirements, model performance, integration costs, data availability and users’ willingness to add automated verification to existing workflows. As such, sinc…
Following the disposition of our biomedical operations, we have maintained a lean, technology-focused operating structure, with personnel primarily engaged in AI research and algorithm engineering, product and software engineering, data and knowledge engineering, customer implementation and commerci…

Text removed vs the prior filing · source: 10-K · 2025-10-08

We are a holding company incorporated in the State of Nevada. We operate through Advanced Biomed Taiwan and Advanced Biomed HK. Advanced Biomed Taiwan is responsible for the main operation and the design and development of the company’s primary technologies and products. Since our establishment in 2…
Our devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients. Among them, A+Pre is mainly used to reduc…
Additionally, we have finished the research and development stage for four matching immunostaining kits, A+CTCE, A+CTCM, A+EMT and A+CM, and submitted registration applications in China. The immunostaining kit use antibodies combined with fluorescent groups of different colors to bind to specific pr…
We also developed a product for early screening of lung cancer, the A+LCGuard Lung Cancer Early Screening Kit (“A+LCGuard”), which is used to assist in the determination of benign and malignant pulmonary nodules. From August 2020 to September 2022, we finalized the research, design, and development …
All of our products must go through three steps to receive the required clearance from the NMPA before they can be sold to customers. The three steps are research and development, registration application, and registration review, which must be done in that order. At the registration application sta…

Risk factors

Text added vs the prior filing · source: 10-K · 2026-10-13

We recently transitioned our business strategy, and our future success is uncertain.
During our most recent fiscal year, we discontinued our biotechnology operations and redirected our resources toward the development of our artificial intelligence platform FinTruth. Because our continuing business differs significantly from our historical operations, investors have limited informat…
The transition to an AI-focused business involves substantial risks, including developing a commercially viable platform, obtaining customer acceptance, competing against significantly larger companies, protecting proprietary technology, securing adequate financing, and generating sustainable revenu…
We have generated limited revenue from our AI-focused operations and may never achieve profitability.
Following the discontinuation of our biotechnology business, our continuing operations are focused primarily on developing our artificial intelligence platform FinTruth. We currently generate no significant revenue from these activities and expect that our future operating results will depend largel…

Text removed vs the prior filing · source: 10-K · 2025-10-08

We are an early stage cancer diagnostics company with a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.
We are at the early stage of commercializing our business. We have not started manufacturing or sales of any products or services. Our limited operating history may make it difficult to evaluate our current business and predict our future performance. Any assessment of our profitability or predictio…
Taiwan and China’s precision oncology detection market is still in its early stage of development and rapidly evolving, and companies operating in this industry face a variety of risks. We may not have sufficient experience or resources to address risks frequently encountered in this industry, which…
● acquire and retain customers and increase adoption of our precision oncology detection products and services by hospitals, physicians, patients, pharmaceutical companies and others in the medical community;
● timely respond to changing market conditions and keep up with evolving industry and technological standards and regulatory developments;

MD&A

Text added vs the prior filing · source: 10-K · 2026-10-13

We are a holding company incorporated in the State of Nevada. During the fiscal year ended June 30, 2026, the Company initiated a strategic corporate restructuring designed to transition its business focus from historical biotechnology activities to the artificial intelligence (“AI”) and financial a…
Historically, we operated through our subsidiaries, Advanced Biomed Inc. (Taiwan) and Advanced Biomed HK Limited (along with its Shanghai subsidiary, Shanghai Sglcell Biotech Co., Ltd.), which were dedicated to the research, design, and regulatory development of our microfluidic technology platform …
● On December 23, 2025, the Company entered into a sale and purchase agreement to sell 100% of its equity interest in Advanced Biomed HK Limited (and its subsidiary) to a third party for a total cash consideration of $23,000.
● On June 30, 2026, the Company entered into a sale and purchase agreement to sell 100% of its equity interest in Advanced Biomed Inc. (Taiwan) to a third party for an aggregate cash consideration of $490,000.
As a result of these divestitures, the Company has concluded all biological research and medical development in biotechnology sections have been phased out. Accordingly, the historical results of operations, assets, and liabilities associated with the biotechnology segment have been reclassified as …

Text removed vs the prior filing · source: 10-K · 2025-10-08

We are a holding company incorporated in the State of Nevada. We operate through Advanced Biomed Taiwan and Advanced Biomed HK. Advanced Biomed Taiwan is responsible for the main operation and the design and development of the company’s primary technologies and products. Since our establishment in 2…
Our devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients. Among them, A+Pre is mainly used to reduc…
A+PerfusC™ system, our latest development, is a compact, all in one perfusion-based 3D cell culture incubator engineered to replicate human physiological conditions to form 3D tumor spheroids/organoids in vitro. The system supports up to 12 days of continuous, hands-free culture, reducing the risk o…
Additionally, we have finished the research and development stage for four matching immunostaining kits, A+CTCE, A+CTCM, A+EMT and A+CM, and submitted registration applications in China. The immunostaining kit use antibodies combined with fluorescent groups of different colors to bind to specific pr…
We also developed a product for early screening of lung cancer, the A+LCGuard Lung Cancer Early Screening Kit (“A+LCGuard”), which is used to assist in the determination of benign and malignant pulmonary nodules. From August 2020 to September 2022, we finalized the research, design, and development …

How to read Risk Factors (Item 1A) in a 10-Q

A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:

Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.

This describes the filing structure only — it is never a judgement on whether risk went up or down.

Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice

More on ADVB

ADVB overview ADVB quant rating ADVB fair value (DCF)ADVB vs peers ADVB revenue history ADVB AI deep research

Section

Outcome

Added

Removed

Minor

Unchanged

Business

Text added/removed

+69

−255

Risk factors

Text added/removed

+64

−247

~26

Legal proceedings

No paragraph-level changes

MD&A

Text added/removed

+91

−94

Market risk (Item 7A)

No paragraph-level changes

Representative excerpts

Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.

Business

Text added vs the prior filing · source: 10-K · 2026-10-13

We are a holding company incorporated in the State of Nevada. In April 2026, we acquired 100% of equity interests of Acellent Technologies (Hong Kong) Co. Limited (“Acellent”), which develops and operates the FinTruth Financial Verification Agent Platform (“FinTruth”), an enterprise AI financial ver…
Prior to our shift to developing our AI application through FinTruth, we were focused on developing lab devices and chemicals in order to find and study cancer cells in a patient’s blood, with the eventual goal of helping doctors detect and monitor cancer through simple blood tests. Our products inc…
Our shift to becoming an AI financial verification company is driven by what we believe are the following key drivers of demand for AI financial verification: (1) the wide use of large language models and AI agents by financial institutions in credit analysis, investment research, risk assessment an…
The market for AI verification remains at an early stage, and adoption will depend on financial institutions’ technology budgets, regulatory requirements, model performance, integration costs, data availability and users’ willingness to add automated verification to existing workflows. As such, sinc…
Following the disposition of our biomedical operations, we have maintained a lean, technology-focused operating structure, with personnel primarily engaged in AI research and algorithm engineering, product and software engineering, data and knowledge engineering, customer implementation and commerci…

Text removed vs the prior filing · source: 10-K · 2025-10-08

We are a holding company incorporated in the State of Nevada. We operate through Advanced Biomed Taiwan and Advanced Biomed HK. Advanced Biomed Taiwan is responsible for the main operation and the design and development of the company’s primary technologies and products. Since our establishment in 2…
Our devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients. Among them, A+Pre is mainly used to reduc…
Additionally, we have finished the research and development stage for four matching immunostaining kits, A+CTCE, A+CTCM, A+EMT and A+CM, and submitted registration applications in China. The immunostaining kit use antibodies combined with fluorescent groups of different colors to bind to specific pr…
We also developed a product for early screening of lung cancer, the A+LCGuard Lung Cancer Early Screening Kit (“A+LCGuard”), which is used to assist in the determination of benign and malignant pulmonary nodules. From August 2020 to September 2022, we finalized the research, design, and development …
All of our products must go through three steps to receive the required clearance from the NMPA before they can be sold to customers. The three steps are research and development, registration application, and registration review, which must be done in that order. At the registration application sta…

Risk factors

Text added vs the prior filing · source: 10-K · 2026-10-13

We recently transitioned our business strategy, and our future success is uncertain.
During our most recent fiscal year, we discontinued our biotechnology operations and redirected our resources toward the development of our artificial intelligence platform FinTruth. Because our continuing business differs significantly from our historical operations, investors have limited informat…
The transition to an AI-focused business involves substantial risks, including developing a commercially viable platform, obtaining customer acceptance, competing against significantly larger companies, protecting proprietary technology, securing adequate financing, and generating sustainable revenu…
We have generated limited revenue from our AI-focused operations and may never achieve profitability.
Following the discontinuation of our biotechnology business, our continuing operations are focused primarily on developing our artificial intelligence platform FinTruth. We currently generate no significant revenue from these activities and expect that our future operating results will depend largel…

Text removed vs the prior filing · source: 10-K · 2025-10-08

We are an early stage cancer diagnostics company with a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.
We are at the early stage of commercializing our business. We have not started manufacturing or sales of any products or services. Our limited operating history may make it difficult to evaluate our current business and predict our future performance. Any assessment of our profitability or predictio…
Taiwan and China’s precision oncology detection market is still in its early stage of development and rapidly evolving, and companies operating in this industry face a variety of risks. We may not have sufficient experience or resources to address risks frequently encountered in this industry, which…
● acquire and retain customers and increase adoption of our precision oncology detection products and services by hospitals, physicians, patients, pharmaceutical companies and others in the medical community;
● timely respond to changing market conditions and keep up with evolving industry and technological standards and regulatory developments;

MD&A

Text added vs the prior filing · source: 10-K · 2026-10-13

We are a holding company incorporated in the State of Nevada. During the fiscal year ended June 30, 2026, the Company initiated a strategic corporate restructuring designed to transition its business focus from historical biotechnology activities to the artificial intelligence (“AI”) and financial a…
Historically, we operated through our subsidiaries, Advanced Biomed Inc. (Taiwan) and Advanced Biomed HK Limited (along with its Shanghai subsidiary, Shanghai Sglcell Biotech Co., Ltd.), which were dedicated to the research, design, and regulatory development of our microfluidic technology platform …
● On December 23, 2025, the Company entered into a sale and purchase agreement to sell 100% of its equity interest in Advanced Biomed HK Limited (and its subsidiary) to a third party for a total cash consideration of $23,000.
● On June 30, 2026, the Company entered into a sale and purchase agreement to sell 100% of its equity interest in Advanced Biomed Inc. (Taiwan) to a third party for an aggregate cash consideration of $490,000.
As a result of these divestitures, the Company has concluded all biological research and medical development in biotechnology sections have been phased out. Accordingly, the historical results of operations, assets, and liabilities associated with the biotechnology segment have been reclassified as …

Text removed vs the prior filing · source: 10-K · 2025-10-08

We are a holding company incorporated in the State of Nevada. We operate through Advanced Biomed Taiwan and Advanced Biomed HK. Advanced Biomed Taiwan is responsible for the main operation and the design and development of the company’s primary technologies and products. Since our establishment in 2…
Our devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients. Among them, A+Pre is mainly used to reduc…
A+PerfusC™ system, our latest development, is a compact, all in one perfusion-based 3D cell culture incubator engineered to replicate human physiological conditions to form 3D tumor spheroids/organoids in vitro. The system supports up to 12 days of continuous, hands-free culture, reducing the risk o…
Additionally, we have finished the research and development stage for four matching immunostaining kits, A+CTCE, A+CTCM, A+EMT and A+CM, and submitted registration applications in China. The immunostaining kit use antibodies combined with fluorescent groups of different colors to bind to specific pr…
We also developed a product for early screening of lung cancer, the A+LCGuard Lung Cancer Early Screening Kit (“A+LCGuard”), which is used to assist in the determination of benign and malignant pulmonary nodules. From August 2020 to September 2022, we finalized the research, design, and development …

How to read Risk Factors (Item 1A) in a 10-Q

A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:

Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.

Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.

Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.

This describes the filing structure only — it is never a judgement on whether risk went up or down.